SCHEMBL4476472

SCHEMBL4476472

CC(C)N1CCN(Cc2ccc(-c3ccccc3Cl)cc2)CC1c1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 7/20 0.57
MAPK1 P28482 2/20 0.47
ALDH1A1 P00352 1/20 0.47
GRM2 Q14416 1/20 0.43
PDE2A O00408 1/20 0.41
PKM P14618 1/20 0.41
CHRNA7 P36544 1/20 0.41
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
LMNA P02545 1/20 0.39
POLB P06746 1/20 0.39
CYP2D6 P10635 1/20 0.39
P2RX7 Q99572 1/20 0.38
GAA P10253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4482477 0.88 CNR2 (0.63) CNR2MAPK1ALDH1A1PDE2APKM
SCHEMBL4489036 0.86 CNR2 (0.64) CNR2MAPK1ALDH1A1PKMMEN1
SCHEMBL4465986 0.85 CNR2 (0.61) CNR2ALDH1A1GRM2PDE2ACHRNA7
SCHEMBL4476194 0.83 CNR2 (0.58) CNR2GRM2PDE2ACHRNA7CYP2D6
SCHEMBL13708808 0.81 CNR2 (0.53) CNR2GRM2PDE2APKMCHRNA7
SCHEMBL4484413 0.80 CNR2 (0.55) CNR2GRM2PDE2ACHRNA7P2RX7
SCHEMBL4487562 0.80 CNR2 (0.55) CNR2GRM2CHRNA7POLBP2RX7
SCHEMBL4472554 0.78 CNR2 (0.55) CNR2PDE2ACHRNA7MEN1KMT2A
SCHEMBL4751823 0.78 CNR2 (0.55) CNR2GRM2PDE2ACHRNA7CYP2D6
SCHEMBL4475198 0.78 CNR2 (0.53) CNR2ALDH1A1GRM2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7595397-B2 Compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-09-29 US disclosed
US-7595397-B2 Compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-09-29 US disclosed
US-7595397-B2 Compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-09-29 US disclosed
EP-1966132-A2 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-09-10 EP disclosed
US-20070191340-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-08-16 US disclosed
US-20070191340-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-08-16 US disclosed
US-20070191340-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-08-16 US disclosed
WO-2007070760-A2 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-06-21 WO disclosed
WO-2007070760-A2 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191340-A1 Compounds Which Modulate The CB2 Receptor CNR1, CNR2, ARRB1 CNR2 2/4885MAPK1 893/4885ALDH1A1 2612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.